SMITHFIELD FIDUCIARY LLC Form SC 13G/A June 10, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A (Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934

(Amendment No. 1) *

GENOME THERAPEUTICS CORP.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
372430108
(CUSIP Number)
June 4, 2003
Date of Event Which Requires Filing of this Statement
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

[] Rule 13d-1 (b)

[x]

[]

Rule 13d-1 (c)

Rule 13d-1 (d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section

of the \mbox{Act} but shall be subject to all other provisions of the \mbox{Act} (however, see the \mbox{Notes}).

CUSIP NO. 3724	13010	8
1. NAME OF REE S.S. or I.F		NG PERSON IDENTIFICATION NO. OF ABOVE PERSON
Smithfi	leld	Fiduciary LLC - not applicable
2. CHECK THE F	APPRO	PRIATE BOX IF A MEMBER OF A GROUP* (a) [X] (b) []
3. SEC USE ONI		
4. CITIZENSHIE	 P OR	PLACE OF ORGANIZATION
		nds, British West Indies
		SOLE VOTING POWER 0
NUMBER OF -		
SHARES	6.	SHARED VOTING POWER
BENEFICIALLY		795,392 shares of Common Stock
OWNED BY EACH		Warrants to purchase shares of Common Stock (exercisable for 389,317 shares of Common Stock) /1/
REPORTING -		
PERSON 7.		
WITH		0
	8.	SHARED DISPOSITIVE POWER See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2

See Row 6 above.

10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	Approximately 4.54% as of the date of this Statement. (Based on 25,684,323 shares of Common Stock issued and outstanding as of June 4, 2003 plus the shares of Common Stock issuable upon the exercise of the Warrants referred to in Row 6 above.)
12.	TYPE OF REPORTING PERSON
	00 - Limited Liability Company
/1/	See Footnote 1 in Item 4.
 CUS	IP NO. 372430108
1.	NAME OF REPORTING PERSON S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
	Highbridge International LLC - not applicable
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X] (b) []
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands, British West Indies
	5. SOLE VOTING POWER 0
NUM	BER OF

SHARES	6.	SHARED VOTING POWER
BENEFICIA	ALLY	795,392 shares of Common Stock
OWNED BY		Warrants to purchase shares of Common Stock (exercisable for 389,317 shares of Common Stock) /1/
EACH		
REPORTING	G	
PERSON	7.	SOLE DISPOSITIVE POWER 0
WITH		·
	8.	SHARED DISPOSITIVE POWER See Row 6 above.
9. AGGRI	EGATE AMOUN	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON
:	See Row 6 a	above.
	K BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11. PERCI	ENT OF CLAS	SS REPRESENTED BY AMOUNT IN ROW (9)
:	25,684,323 June 4, 200	ely 4.54% as of the date of this Statement. (Based on shares of Common Stock issued and outstanding as of 03 plus the shares of Common Stock issuable upon the f the Warrants referred to in Row 6 above.)
12. TYPE	OF REPORT	ING PERSON
(OO − Limite	ed Liability Company
/1/ See 1	Footnote 1	in Item 4.
CUSIP NO	. 37243010	08
1. NAME S.S.	OF REPORTI	ING PERSON IDENTIFICATION NO. OF ABOVE PERSON Capital Corporation - not applicable

2. CHECK THE	E APPRO	PRIATE BOX IF A MEMBER OF A GROUP*	(a) (b)	
3. SEC USE (ONLY			
		PLACE OF ORGANIZATION nds, British West Indies		
	5.	SOLE VOTING POWER		
NUMBER OF	 6.	SHARED VOTING POWER		
BENEFICIALLY		795,392 shares of Common Stock		
OWNED BY		Warrants to purchase shares of Common Stock for 389,317 shares of Common Stock		ock (exercisable
REPORTING				
PERSON	7.	SOLE DISPOSITIVE POWER 0		
	8.	SHARED DISPOSITIVE POWER See Row 6 above.		
	E AMOUN	T BENEFICIALLY OWNED BY EACH REPORT	ING PE	 RSON
10. CHECK BOX		E AGGREGATE AMOUNT IN ROW (9) EXCLU	JDES CE	RTAIN SHARES*
11. PERCENT (S REPRESENTED BY AMOUNT IN ROW (9)		
25,68	34,323	ly 4.54% as of the date of this Sta shares of Common Stock issued and o 3 plus the shares of Common Stock i	outstan	ding as of

exercise of the Warrants referred to in Row 6 above.)

12. TYPE OF RE	PORTI	ING PERSON	
00 - L	imite	ed Liability Company	
/1/ See Footno		in Item 4.	
CUSIP NO. 372	43010	08	
1. NAME OF RE S.S. or I.		ING PERSON IDENTIFICATION NO. OF ABOVE PERSON	
Highbr	idge	Capital Management, LLC - 13-3993048	
2. CHECK THE	 APPRO	DPRIATE BOX IF A MEMBER OF A GROUP*	
		(a) [X] (b) []	
3. SEC USE ON	LY		
4. CITIZENSHI	 P OR	PLACE OF ORGANIZATION	
State	of De	elaware	
	5.	SOLE VOTING POWER 0	
NUMBER OF			
SHARES	6.	SHARED VOTING POWER	
BENEFICIALLY		795,392 shares of Common Stock	
OWNED BY		Warrants to purchase shares of Common Stock (e. for 389,317 shares of Common Stock) /1/	xercisable
EACH		101 307, 317 Shares of Common Scock, 717	
REPORTING			
PERSON	7.	SOLE DISPOSITIVE POWER	
WITH		0	

	8. SHARED DISPOSITIVE POWER See Row 6 above.
 9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Row 6 above.
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	Approximately 4.54% as of the date of this Statement. (Based on 25,684,323 shares of Common Stock issued and outstanding as of June 4, 2003 plus the shares of Common Stock issuable upon the exercise of the Warrants referred to in Row 6 above.)
12.	TYPE OF REPORTING PERSON
	00 - Limited Liability Company
/1/	See Footnote 1 in Item 4.
Iten	n 1.
(a)	Name of Issuer
	Genome Therapeutics Corp.
(b)	Address of Issuer's Principal Executive Offices:
	100 Beaver Street Waltham, Massachusetts 02453
Iten	n 2(a). Name of Person Filing n 2(b). Address of Principal Business Office n 2(c). Citizenship

Smithfield Fiduciary LLC The Anchorage Centre, 2nd Floor

Harbor Drive, George Town, Grand Cayman, Cayman Islands, British West Indies Citizenship: Cayman Islands, British West Indies

Highbridge International LLC
The Anchorage Centre, 2nd Floor
Harbor Drive, George Town,
Grand Cayman, Cayman Islands, British West Indies
Citizenship: Cayman Islands, British West Indies

Highbridge Capital Corporation
The Anchorage Centre, 2nd Floor
Harbor Drive, George Town,
Grand Cayman, Cayman Islands, British West Indies
Citizenship: Cayman Islands, British West Indies

Highbridge Capital Management, LLC 9 West 57th Street, 27th Floor New York, New York 10019 Citizenship: State of Delaware

- (d) Title of Class of Securities Common Stock, par value \$.10 per share
- (e) CUSIP Number 372430108

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

- (a) [] Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).
- (b) [] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) [] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) [] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) [] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) [] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) [] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) [] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) [] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) [] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1(c), check this box. [X]

Item 4. Ownership

(a) Amount Beneficially Owned

795,392 shares of Common Stock

Warrants to purchase shares of Common Stock (exercisable for 389,317 shares of Common Stock) /1/

(b) Percent of Class

Approximately 4.54% as of the date of this Statement. (Based on 25,684,323 shares of Common Stock issued and outstanding as of June 4, 2003 plus the shares of Common Stock issuable upon the exercise of the Warrants referred to in item (a) above.)

- (c) Number of shares as to which such person has:
 - (i) sole power to vote or to direct the vote $\boldsymbol{0}$
 - (ii) shared power to vote or to direct the vote $$\operatorname{See}$$ item (a) above.
 - (iii) sole power to dispose or to direct the disposition of $\ensuremath{\text{0}}$
 - (iv) shared power to dispose or to direct the disposition of See item (a) above.

/1/ On June 4, 2003, the Issuer entered into an Amendment, Redemption and Exchange Agreement dated as of June 4, 2003 (the "Agreement") with Smithfield Fiduciary LLC ("Smithfield"). The Agreement provided for (a) the redemption in cash of \$8,000,000 principal amount of the 6% Convertible Notes due December 31, 2004 of the Issuer (the "Convertible Notes") (plus accrued and unpaid interest thereon) held by Smithfield, (b) the conversion of the remaining \$4,000,000 principal amount of the Convertible Notes (plus accrued and unpaid interest thereon) held by Smithfield into 1,596,947 shares of Common Stock at an amended conversion price of \$2.5686 and (c) the issuance to Smithfield of warrants to purchase up to 389,317 shares of Common Stock (the "Exchange Warrants") in exchange for warrants to purchase up to 390,000 shares of Common Stock previously held by Smithfield.

Reference is made to the Agreement and the form of Exchange Warrants attached as Exhibits 4.1 and 4.3, respectively, to the Issuer's Current Report on Form 8-K filed on June 5, 2003, which are incorporated herein by reference, and the description herein is qualified in its entirety by the Agreement and form of Exchange Warrants.

The securities reported herein include securities that the Reporting Persons may acquire in the future through the exercise of the Exchange Warrants at any time and from time to time prior to and including June 4, 2008. The exercise price of the Exchange Warrants is \$3.71 (subject to adjustment to prevent dilution).

Pursuant to the terms of the Exchange Warrants, the Reporting Persons cannot be "beneficial owners" of more than 4.99% of the Common Stock within the meaning of Rule 13d-1 of the Act upon exercise of the Exchange Warrants.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following $[\ X\].$

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Inapplicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

See Item 2 above.

Item 8. Identification and Classification of Members of the Group

Inapplicable

Item 9. Notice of Dissolution of Group

Inapplicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose of effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated this 10th day of June, 2003

Smithfield Fiduciary LLC

By: /s/ Howard Feitelberg

Howard Feitelberg, Director

Highbridge International LLC

By: /s/ Howard Feitelberg

Howard Feitelberg, Director

Highbridge Capital Corporation

By: /s/ Howard Feitelberg

Howard Feitelberg, Controller

Highbridge Capital Management, LLC

By: /s/ Ronald S. Resnick
----Ronald S. Resnick, Managing Director

Exhibit Index

Exhibit	Description
1	Joint Filing Agreement
2	Amendment, Redemption and Exchange Agreement by and between Genome Therapeutics Corp. and Smithfield Fiduciary LLC dated as of June 4, 2003 (incorporated by reference to Exhibit 4.1 to the Issuer's Current Report on Form 8-K filed on June 5, 2003).
3	Form of Exchange Warrants issued to Smithfield Fiduciary LLC (incorporated by reference to Exhibit 4.3 to the Issuer's Current Report on Form 8-K filed on June 5, 2003).